OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Nghiem on Response to Immunotherapy in Merkel Cell Carcinoma

July 31st 2018

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses response to immunotherapy in Merkel cell carcinoma.

Dr. Yardley on the D-CARE Trial in Women With High-Risk Early Breast Cancer

July 31st 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the D-CARE trial in women with high-risk early breast cancer.

Dr. Yee on Neoadjuvant Therapy for Triple-Negative Breast Cancer

July 30th 2018

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplant, medical oncologist, University of Minnesota, discusses neoadjuvant therapy for patients with triple-negative breast cancer.

Dr. Sparano on Application of Liquid Biopsies in Breast Cancer

July 30th 2018

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses the application of liquid biopsies in breast cancer.

Dr. Woodward on Proton Radiotherapy in Breast Cancer

July 27th 2018

Wendy A. Woodward, MD, PhD, professor and chief, Clinical Breast Radiotherapy Service, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses proton radiotherapy in breast cancer.

Dr. Lynch on the Goals of Bristol-Myers Squibb

July 27th 2018

Thomas Lynch, Jr, MD, Vice President and Chief Scientific Officer at Bristol-Myers Squibb, discusses goals at Bristol-Myers Squibb.

Dr. Shunyakov on the Impact of Genomics on Personalized Therapy in Oncology

July 27th 2018

Leonid Shunyakov, MD, hematologist/oncologist, Central Care Cancer Center, discusses how genomics have impacted personalized therapy in oncology.

Dr. Lynch on the Immuno-Oncology Network at Bristol-Myers Squibb

July 27th 2018

Thomas Lynch, Jr, MD, Vice President and Chief Scientific Officer at Bristol-Myers Squibb, discusses the Immuno-Oncology (IO) Network at Bristol-Myers Squibb.

Dr. Aggarwal on Triplet Therapy in EGFR-Mutant Lung Cancer

July 27th 2018

Charu Aggarwal, MD, assistant professor of Medicine, University of Pennsylvania, discusses triplet therapy in EGFR-mutant lung cancer.

Dr. Bauml on Emerging Biomarkers in NSCLC

July 27th 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses emerging biomarkers in non–small cell lung cancer (NSCLC).

Dr. Grossman Discusses TTFields for Glioblastoma

July 27th 2018

Rachel Grossman, MD, Neurosurgery Department, Tel Aviv Sourasky Medical Center, discusses tumor treating fields for the treatment of patients with glioblastoma.

Dr. Pollyea Discusses Recent Advances in AML

July 27th 2018

Daniel A. Pollyea, MD, MS, assistant professor of Medicine at the University of Colorado Cancer Center and clinical director of Leukemia Services at the CU School of Medicine, discusses recent advances in the treatment landscape of acute myeloid leukemia.

Dr. Ansell Discusses Immune Evasion in Lymphoma

July 27th 2018

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses immune invasion in lymphoma.

Dr. Esserman on Personalized Screenings for Breast Cancer

July 26th 2018

Laura Esserman, MD, MBA, professor, University of California, San Francisco, discusses personalized versus annual screenings for breast cancer.

Dr. Rogers on Reducing Risk of Tumor Lysis Syndrome in CLL

July 26th 2018

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses reducing the risk of tumor lysis syndrome during the treatment of patients with chronic lymphocytic leukemia.

Dr. Tripathy on the Importance of Biosimilars in Oncology

July 26th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of biosimilars in oncology.

Dr. Murthy on Caveats of the PERSEPHONE Trial in Breast Cancer

July 26th 2018

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses caveats of the PERSEPHONE trial.

Dr. Goy on the Evolution of Treatment in Mantle Cell Lymphoma

July 26th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolution of treatment in mantle cell lymphoma (MCL).

Dr. Wistinghausen on Developing Drugs for Children With Cancer

July 25th 2018

Birte Wistinghausen, MD, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses developing drugs for children with cancer.

Dr. Kahl Discusses the Potential of Frontline Ibrutinib in MCL

July 25th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the potential of frontline ibrutinib (Imbruvica) in the treatment of patients with mantle cell lymphoma.